Feb. 4, 2026 — A new review published in the American Journal of Roentgenology (AJR) finds that advances in CT technology over the past 25 years have enabled routine radiation dose reductions by a factor of 2 to 10, while preserving diagnostic performance when applied appropriately.

Feb. 4, 2026 — On World Cancer Day (02.04.26), the American Society for Radiation Oncology (ASTRO) and the European Society for Radiotherapy and Oncology (ESTRO) together are calling for greater awareness of what today’s radiotherapy offers to patients and the global health care system: a cornerstone of modern, multidisciplinary cancer care, grounded in precision, personalization and continuous innovation.

Feb. 4, 2026 — The Royal College of Radiologists (RCR) has issued its initial reaction to the British government's recently-released National Cancer Plan for England. 

The Plan reflects priorities long highlighted by the RCR, the body representing senior doctors responsible for cancer diagnosis and treatment, to:  

Jan. 29, 2026 — GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MIM LesionID Pro,1 an innovative solution from its MIM software portfolio that transforms whole-body tumor burden analysis for PSMA PET/CT and SPECT/CT studies into a significantly simplified process.

Feb. 2, 2026 — Imagion Biosystems, Ltd. has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its MagSense targeted imaging agent. Following FDA approval, the company expects to start a Phase 2 clinical trial with the imaging agent for the detection of nodal metastases in HER2+ breast cancer patients.

Feb. 2, 2026 — GE HealthCare has announced that Allia Moveo has received U.S. Food and Drug Administration (FDA) 510(k) clearance and CE Marking, bringing next-level mobility and precision to the interventional suite.

Jan. 29, 2026 — The American Society for Radiation Oncology (ASTRO) has launched a national program creating Authorized User (AU) Training Centers for physicians wanting to provide radiopharmaceutical therapy. This initiative is designed to expand patient access and increase the number of physicians certified to provide the safe delivery of these emerging cancer treatments.

Jan. 22, 2026 — In breast cancer, a biopsy is the only diagnostic procedure that can determine if a suspicious lump or area is cancerous. However, in the U.S., between 75% and 80% of breast biopsies are benign.

Jan. 27, 2026 —  Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading institutions across the country, have published a new study that provides radiation oncologists with practical guidance to identify and protect female sexual organs during pelvic cancer treatment.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now